[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.52.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,335
Citations 0
Editorial
September 2015

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?

Author Affiliations
  • 1Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland
  • 2Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
  • 3Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
 

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Oncol. 2015;1(6):732-733. doi:10.1001/jamaoncol.2015.1926

The study in this issue of JAMA Oncology by Bandera et al1 evaluated the association of body mass index (BMI) and chemotherapy dosing, and the authors related relative dose intensity (RDI) to overall and ovarian cancer–specific mortality. This retrospective cohort analysis was based on the Kaiser Permanente Research on Ovarian Cancer Study of Epithelial Ovarian Cancer chemotherapy subcohort (806 patients). Importantly, it is a relatively unselected real-world cohort, and one of the largest studied to date. The investigators concluded that lower RDI of paclitaxel and carboplatin was associated with diminished survival in women treated for ovarian cancer, which further confirms observations by others.2-5

×